TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

Update: 2024-07-04

Description

We love to hear from our listeners. Send us a message.

KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. In addition to solid tumors, Benson also addresses the therapeutic potential for autoimmune disease.

Subscribe to the podcast!
Apple | Spotify | YouTube

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene

2024-11-2121:39

Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

2024-11-0720:52

Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte

2024-10-2425:26

Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D.

2024-10-1014:18

Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge

2024-09-2522:00

A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino

2024-09-1228:06

Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

2024-08-2925:13

CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D.

2024-08-1527:58

Identifying Drug Development Opportunities for DMD with CureDuchenne

2024-08-0129:55

Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington

2024-07-1821:01

TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

2024-07-0435:30

Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft

2024-06-2027:52

Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko

2024-06-0614:52

The Current State of the Global Regulatory Landscape with ISCT's Dr. Bambi Grilley

2024-05-2825:21

Dr. Bruce Levine on ISCT and the Future of CAR-T

2024-05-2331:49

CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant

2024-05-0918:51

Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah

2024-04-2529:39

Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang

2024-04-1123:08

Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan

2024-03-2819:37

Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D.

2024-03-1417:17

00:00

TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

#box-pro-ellipsis-173224210719923{-webkit-line-clamp:2;}TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

Erin Harris

TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.